DYRK1A Signaling in the Brain: Molecular Mechanisms and Neurotransmitter Regulation

DYRK1A (dual-specificity tyrosine phosphorylation-regulated kinase 1A) is a dosage-sensitive regulator of central nervous system development. Dysregulation contributes to major neurodevelopmental disorders, including Down Syndrome (DS), Autism Spectrum Disorder (ASD), and Intellectual Developmental Disorder (IDD). This review critically examines how DYRK1A dosage shapes neurodevelopment, neurotransmitter regulation, and disease phenotypes.

We synthesized molecular, cellular, and systems-level evidence (2015-2025) from rodent DYRK1A mutant models, human iPSC-derived neural progenitors, and human transcriptomic datasets using comprehensive searches of PubMed, Google Scholar, and Web of Science. Studies were assessed for mechanistic rigor, species applicability, and translational potential.

Recent studies reveal that DYRK1A coordinates four neurodevelopmental processes: (1) neural progenitor proliferation/differentiation via cell cycle regulation (cyclin D1, p27Kip1, E2F2, NeuroD1); (2) chromatin remodeling through histone acetyltransferase phosphorylation (EP300, CREBBP); (3) glutamatergic synaptic transmission via presynaptic gene suppression (RIMS1, Munc13-1, Syn2), impairing NMDA-independent long-term potentiation; (4) glial differentiation and myelination. DYRK1A overexpression in DS disrupts neurogenesis and synaptic connectivity; haploinsufficiency causes microcephaly and intellectual disability. Species divergence between rodent and human iPSC models, combined with inter-individual variability, underscores the limitations of current mechanistic models.

DYRK1A functions as a dosage‑sensitive regulator orchestrating neurogenesis, chromatin remodeling, synaptic transmission, and glial maturation. Evidence from rodent and human iPSC models underscores mechanistic divergence and inter‑individual variability, complicating translational pathways. Therapeutic strategies, such as small‑molecule inhibitors, CRISPR‑Cas9, and antisense oligonucleotides, show promise but require precise titration to restore equilibrium. Personalized iPSC models, biomarker development, and longitudinal monitoring remain essential for advancing precision medicine approaches targeting dosage‑sensitive genes like DYRK1A.

Therapeutic strategies, such as small-molecule inhibitors (EGCG, harmine), CRISPR-Cas9, and antisense oligonucleotides, demonstrate preclinical efficacy but require precise dosage titration to restore physiological equilibrium without disrupting neurogenic processes. Clinical translation necessitates personalized iPSC models, biomarkers, and longitudinal monitoring. DYRK1A exemplifies precision medicine for dosage-sensitive genes where therapeutic success depends on restoring physiological balance.